Clinical trials: Depressive Disorder NOS
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Major Depressive Disorder
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
The purpose of this study is to determine the effect of LY2216684 on heart rate and blood pressure in research participants with MDD who are being treated with an SSRI (selective serotonin reuptake inhibitors).
- Trial name
- NCT01263223
- Testing
- LY2216684
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Bipolar Depression
PET and MRI Brain Imaging of Bipolar Disorder
The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2.
- Conditions
- Bipolar Disorder, Bipolar Depression, Unipolar Depression
- Trial name
- NCT01880957
- Testing
- Lithium, Lamotrigine
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Adjunctive Treatment of Major Depressive Disorder
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
- Trial name
- NCT04000009
- Testing
- Pimavanserin
- Where
- 71 sites in United States, Finland and 7 more
- Volunteers
- 235 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
Major Depressive Disorder
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
- Trial name
- NCT03737474
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Depression, Unipolar
Repeated Neurocognitive Measurements in Depressed Patients
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning…
- Trial name
- NCT04916548
- Testing
- Intravenous Ketamine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rebecca Price
Depressive Disorders, Alcohol Use Disorders
Implementing a Blended Care Model That Integrates Mental Healthcare and Primary Care Using Telemedicine and Care Management for Patients With Depression or Alcohol Use Disorder in Small Primary Care Clinics
Integrating mental health treatments into the primary care delivered at Community Based Outpatient Clinics(CBOCs) that are geographically accessible to rural Veterans is a major priority for the Department of Veterans Affairs.
- Conditions
- Depressive Disorders, Alcohol Use Disorders, Post-traumatic Stress Disorder (PTSD)
- Trial name
- Tele-PCMHI (NCT02713217)
- Testing
- Usual Care, Blended Telemedicine-Based Integrated Care
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Modeling Multi-level Dyadic Behavior to Transform the Science and Practice of Psychotherapy Process and Outcome.
This is a short-term longitudinal study of psychotherapy process. Participants will be treated with 8 sessions of psychotherapy over the course of 8 to 12 weeks.
- Trial name
- DAPPeR (NCT03594773)
- Testing
- Cognitive Behavioral Therapy, Interpersonal Psychotherapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together.
- Trial name
- NCT01243957
- Testing
- LY2216684, Fluoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
PostPartum Depression
The Effect of Exercise on Preventing PostPartum Depression
The purpose of this study is to examine the feasibility and efficacy of an exercise intervention for the prevention of postpartum depression.
- Trial name
- NCT00961402
- Testing
- Wellness Control, Exercise Intervention
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Major Depression
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit…
- Trial name
- NCT04446039
- Testing
- Escitalopram, Paroxetine, Fluoxetine
- Where
- South Korea
- Volunteers
- 370,212 people
- Sponsor
- Pfizer
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Dysthymia Disorder
Oxytocin Add-on for Stable Depressed Patients
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve depression symptoms in patients with Major Depressive Disorder (MDD) or Dysthymia Disorder.
- Trial name
- NCT01211756
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- David Feifel
Treatment Resistant Depression
Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
The primary goal of the project is to study the effect of Ketamine on cortical neurophysiological function in TRD patients. The proposal employs robust and non-invasive neurophysiological techniques TMS and EEG to investigate the…
- Trial name
- ketamine (NCT02935595)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center, Houston
Adjunctive Treatment of Major Depressive Disorder
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy.
- Trial name
- NCT04103892
- Testing
- CLE-100
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 146 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
- Trial name
- VLZ-MD-23 (NCT02436239)
- Testing
- Vilazodone
- Where
- 56 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Forest Laboratories
Bipolar Disorder, Major Depressive Disorder
Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms
The purpose of this study is to advance a non-pharmacologic suicide preventive intervention with wide dissemination potential as an innovative high-yield solution to reduce suicide rates.
- Conditions
- Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide
- Trial name
- NCT05317481
- Testing
- BE-SMART-DR, psychoeducational control comparator condition (CC)
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Yale University
Depressive Disorder
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
This study is designed to compare the efficacy of oral paroxetine 10 to 40 mg/day (initial dose:10 mg/day) versus placebo administered once daily (after evening meal) for 8 weeks in children and adolescents with major depressive…
- Trial name
- NCT00812812
- Testing
- paroxetine 10mg tablet, paroxetine 20mg tablet
- Where
- 33 sites in Japan
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline